TABLE 2.
Baseline characteristics in the validation cohort.
| Characteristics | TACE-refractory group (n = 95) | TACE-non-refractory group (n = 27) | p Value |
|---|---|---|---|
| Age, yr, mean (range) | 59.42 (27–92) | 60.41 (36–85) | 0.716 |
| Sex (male/female) | 77/18 (81%) | 19/8 (70%) | 0.287 |
| Hepatitis B (yes/no) | 53/42 (56%) | 18/9 (66%) | 0.380 |
| PS (0/1) | 75/20 (79%) | 18/9 (66%) | 0.206 |
| TBIL (μmol/L), mean ± SD | 17.37 ± 8.51 | 20.58 ± 9.07 | 0.081 |
| ALB (g/L), mean ± SD | 39.44 ± 5.02 | 37.91 ± 4.36 | 0.167 |
| AST (IU/L), mean ± SD | 79.56 ± 205.70 | 65.33 ± 61.34 | 0.482 |
| ALT (IU/L), mean ± SD | 63.61 ± 153.07 | 50.32 ± 40.18 | 0.788 |
| WBC (109/L), mean ± SD | 6.24 ± 2.55 | 5.42 ± 1.88 | 0.123 |
| Hb (g/L), mean ± SD | 131.95 ± 20.64 | 133.44 ± 19.14 | 0.736 |
| BCLC stage (A/B) | 1/94 (1%) | 3/24 (11%) | 0.034 |
| HKLC stage (I/II/III) | 11/40/44 | 7/13/7 | 0.074 |
| TN, mean ± SD | 3.44 ± 1.09 | 2.89 ± 1.16 | 0.032 |
| TD, cm, mean ± SD | 8.20 ± 4.20 | 6.45 ± 3.50 | 0.051 |
| BI (yes/no) | 34/61 (36%) | 6/21 (22%) | 0.247 |
PS: physical status; TBIL: total bilirubin; ALB: albumin; AST: aspartate transaminase; ALT: alanine aminotransferase; WBC: white blood cell count; TN: tumor number; TD: tumor diameter; BI: bilobular invasion; SD: standard deviation.